Literature DB >> 11583905

Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction.

C M Yu1, G L Tipoe, K Wing-Hon Lai, C P Lau.   

Abstract

OBJECTIVES: The goal of this study was to compare the relative efficacy of an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) in suppressing the histopathologic changes that lead to ventricular remodeling after an acute myocardial infarction (AMI).
BACKGROUND: Myocardial interstitial fibrosis in the noninfarcted region is a major histologic landmark resulting in cardiac dysfunction after AMI. However, the relative potency of an ACE inhibitor and ARB on suppressing the histopathologic changes was unclear.
METHODS: Rats with AMI were randomized to fosinopril, valsartan or a combination of the two drugs for two or four weeks. The total, type I and type III collagen and activated fibroblasts and macrophages were quantified by histomorphometry. The expression of transforming growth factor-beta 1 (TGF-beta 1) messenger ribonucleic acid (mRNA) was determined by reverse transcription polymerase chain reaction.
RESULTS: Acute myocardial infarction resulted in significant elevation of total (p < 0.001) and type I (p < 0.001) collagen and a twofold increase in TGF-beta 1 mRNA expression (p < 0.001) in the septum at two and four weeks. Macrophages and activated myofibroblasts infiltrated extensively in the infarct zone. Treatment with valsartan or combination therapy normalized the total and type I collagen (p < 0.001) as well as TGF-beta 1 mRNA level (p < 0.01) in the septum and was associated with the suppression of macrophages and myofibroblasts in the infarct zone (p < 0.01). Fosinopril was less effective than valsartan or combination therapy.
CONCLUSIONS: The use of valsartan, especially combined with fosinopril, was more effective than fosinopril in the suppression of histopathologic changes resulting in cardiac remodeling after AMI. This study has important therapeutic implications in pharmacotherapy of clinical practice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583905     DOI: 10.1016/s0735-1097(01)01518-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  31 in total

Review 1.  Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2008-02-07       Impact factor: 4.214

Review 2.  Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.

Authors:  Hassan K Awada; Mintai P Hwang; Yadong Wang
Journal:  Biomaterials       Date:  2015-12-29       Impact factor: 12.479

Review 3.  Transforming growth factor (TGF)-β signaling in cardiac remodeling.

Authors:  Marcin Dobaczewski; Wei Chen; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2010-11-06       Impact factor: 5.000

4.  Platelet-derived growth factor blockade on cardiac remodeling following infarction.

Authors:  Chang Liu; Wenyuan Zhao; Weixin Meng; Tieqiang Zhao; Yuanjian Chen; Robert A Ahokas; Hongyu Liu; Yao Sun
Journal:  Mol Cell Biochem       Date:  2014-08-23       Impact factor: 3.396

5.  A possible anti-inflammatory role of angiotensin II type 2 receptor in immune-mediated glomerulonephritis during type 1 receptor blockade.

Authors:  Hirokazu Okada; Tsutomu Inoue; Tomohiro Kikuta; Yusuke Watanabe; Yoshihiko Kanno; Shinichi Ban; Takeshi Sugaya; Masatsugu Horiuchi; Hiromichi Suzuki
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

Review 6.  Myocardial repair/remodelling following infarction: roles of local factors.

Authors:  Yao Sun
Journal:  Cardiovasc Res       Date:  2008-12-02       Impact factor: 10.787

Review 7.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

8.  Effect of Losartan on Mitral Valve Changes After Myocardial Infarction.

Authors:  Philipp E Bartko; Jacob P Dal-Bianco; J Luis Guerrero; Jonathan Beaudoin; Catherine Szymanski; Dae-Hee Kim; Margo M Seybolt; Mark D Handschumacher; Suzanne Sullivan; Michael L Garcia; James S Titus; Jill Wylie-Sears; Whitney S Irvin; Emmanuel Messas; Albert A Hagège; Alain Carpentier; Elena Aikawa; Joyce Bischoff; Robert A Levine
Journal:  J Am Coll Cardiol       Date:  2017-09-05       Impact factor: 24.094

9.  Cardiotrophin-1: expression in experimental myocardial infarction and potential role in post-MI wound healing.

Authors:  Darren H Freed; Michael C Moon; Anna M Borowiec; Stephen C Jones; Peter Zahradka; Ian M C Dixon
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

Review 10.  The immune system and cardiac repair.

Authors:  Nikolaos G Frangogiannis
Journal:  Pharmacol Res       Date:  2008-06-24       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.